About Angimmune - Developer of Resimmune, an Anti-T Cell Immunotoxin Home About Approach Clinical Trials Early Results Future Directions The Company Angimmune LLC is a new small... at NIH these founders developed a unique immunotoxin technology. Angimmune has now licensed this technology from NIH. Angimmune conducts research in a facility located on Medical Center... and clinical trial evaluation of our new immunotoxin platform. Founders Dr. David Neville Dr. David Neville is the President and Chief Scientific Officer of Angimmune LLC. He...

of a lymphocyte cell New Clinical Trials With Anti-CD3 Immunotoxin In Planning Stage Autoimmune disease trials with anti-T cell immunotoxin Resimmune The hypothesis that transient... profound T cell depletion via immunotoxin followed by homeostatic repopulation can lead to the "resetting" of the immune system and a reversal of autoimmune disease has been proposed... not uniformly bearing surface CD3 T-ALL with at least 10% of T-ALL blasts expressing surface CD3e Metastatic malignant melanoma Pipeline Immunotoxins directed at other hematologic...

Angimmune LLC - Developer of Resimmune, an Anti-T Cell Immunotoxin Home About Approach Clinical Trials Early Results Future Directions T cell Targeting for Cancers and Autoimmune... Diseases Reference Sustained Effect Theory Angimmune LLC's anti-T cell immunotoxin is being investigated for treatment of T cell blood cancers and other applications. Angimmune LLC... is the developer of a high potency fusion protein anticancer immunotoxin, A-dmDT390-bisFv (UCHT1) (Resimmune). This unique bivalent anti-T cell immunotoxin therapy works in two...

of the anti-T cell bivalent immunotoxin Resimmune (IND No. 100712, clinical trial identifier NCT00611208) at Scott & White Memorial Hospital, Temple TX under the direction of Arthur Frankel... Immunotoxin Therapy of Cutaneous T Cell Lymphoma (CTCL). These results have not established safety or clinical efficacy. However, a number of interesting observations have been made... are published. Sustained Effect Theory This immunotoxin kills both malignant and normal T cells, however the normal T cells begin to repopulate within ten days from the periphery. This...